Press release – Berlin/New York, 24 January 2023
• tenacio’s OptiCorTM Clinical Decision Support Tool is an easy-to-use
tool for clinicians to optimize treatment for patients with atrial
fibrillation
• OptiCorTM has shown significant reductions in mortality and stroke
in a previously published study¹
tenacio, whose mission is to improve clinical outcomes for cardiovascular
patients and to reduce healthcare costs, announced its OptiCor patient
management platform is now commercially available in the US following a
completed review by the U.S. Food and Drug Administration (FDA).
Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting one out
of three individuals during their lifetime. It can result in strokes, hospitalizations, and
pre-mature death. Registries showed that 40% of these patients are not optimally
treated. OptiCorTM is a patient management platform to address this unmet need
through clinically meaningful prediction of events such that patients and providers
can make more informed collective decisions about disease management. It has
demonstrated its potential for significant reductions in outcome events in a 52,000
patient in-silico study1
.
“Still today, many patients with atrial fibrillation are not treated optimally and
therefore suffer unnecessarily from strokes and premature deaths. Tools which
support physicians in treating their patients according to guidelines are urgently
needed.” says Professor Christopher B. Granger from Duke University, NC, USA.
“The launch of OptiCor in the US following an FDA review marks an important
milestone for tenacio. Using OptiCor is expected to result in better outcomes for
cardiovascular patients.” says Dr Georg van Husen, M.D., CEO of tenacio.
OptiCorTM is a digital decision support tool with a proprietary risk prediction
algorithm combined with curated clinical evidence and guideline-based patient
treatment recommendations. It has been designated by the FDA as a Clinical
Decision Support Software.
About tenacio
tenacio is digitizing cardiovascular care to improve patient outcomes and reduce
healthcare costs by transforming cardiovascular disease management using
state-of-the-art technology and leading-edge science to provide dynamic and
individualized care for patients.
www.tenac.io
Press contact
Georg van Husen, co-founder & CEO
georg.van_husen@tenac.io
p +49-151-260 74154
tenac.io GmbH
Berlin, Germany
tenac.io. Inc.
447 Broadway, 2nd floor
New York, NY 10013
United States
P (212)-252-2168
¹ G v Husen et al., Universal Clinician Device for improving risk prediction and management of patients with atrial
fibrillation: an assumed benefit analysis, European Heart Journal – Digital Health, Volume 3, Issue 2 2022
